Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board ...

Harvard Bioscience (HBIO) announced a CEO succession plan under which John Duke will assume the role of president & CEO following the planned retirement of Jim Green, effective July 28, 2025.

Windtree Therapeutics, a Nasdaq listed biotechnology company, has plans to raise up to $200 million to build a treasury of ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

New leadership to spearhead AI-driven breakthroughs in drug discovery and operational excellence Austin, Texas--(Newsfile ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards ...

According to market observers, shares of the company are available at a premium of ₹156 in the grey market today ...

Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 7, ...

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 '25 revenue anticipated to be $20.4 million and Company reiterates pr ...

Anthem Biosciences IPO allotment status online check can be done through the websites of BSE and NSE, along with the official ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...